WM-115 Cells
US$ 1.000,00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
Informações gerais
| Descrição | WM-115 is a human melanoma cell line derived from the primary tumor of an adult patient with cutaneous malignant melanoma. The cell line was established from a vertical growth phase (VGP) primary lesion and is part of a well-characterized series of melanoma models generated to represent distinct stages of melanoma progression. WM-115 cells grow adherently in vitro and display an epithelioid to spindle-shaped morphology typical of malignant melanocytes. Cytogenetic analyses of related primary and metastatic pairs have demonstrated non-random chromosomal abnormalities, particularly involving chromosomes 1, 6, and 7, supporting clonal evolution during melanoma progression. Phenotypically, WM-115 expresses melanocytic lineage markers and melanoma-associated antigens, including pigmentation-related proteins and cell surface adhesion molecules. Compared to non-invasive radial growth phase lesions, vertical growth phase melanoma cells such as WM-115 exhibit increased expression of adhesion-related molecules, including integrins and extracellular matrix-associated proteins, reflecting enhanced invasive potential. Melanoma cells commonly express receptors for growth factors such as IGF-I and, variably, EGF receptor family members, supporting autocrine and paracrine growth stimulation mechanisms. Functionally, WM-115 represents a model of primary melanoma with metastatic competence emerging at the vertical growth phase stage. Unlike normal melanocytes, which require multiple exogenous mitogens for proliferation, primary melanoma cells such as WM-115 display reduced dependence on external growth factors and may proliferate under more permissive culture conditions. As a primary tumor-derived melanoma model, WM-115 is widely used to study melanoma progression, invasion-associated phenotypes, growth factor signaling, and therapeutic response in comparison with metastatic counterparts derived from the same or related patients. |
|---|---|
| Organismo | Human |
| Tecido | Metastatic |
| Doença | Melanoma |
| Local da metástase | Right anterior leg, skin |
| Sinônimos | WM-115, WM 115, WM115F, WM115-mel, WM115mel, WC00079 |
Características
| Idade | 55 years |
|---|---|
| Gênero | Female |
| Etnia | Caucasian |
| Propriedades de crescimento | Adherent |
Dados regulatórios
| Referência | WM115 (Cytion catalog number 305457) |
|---|---|
| Nível de biossegurança | 1 |
| NCBI_TaxID | 9606 |
| Número de acesso do Cellosaurus | CVCL_0040 |
Dados biomoleculares
| Perfil mutacional | Mutation: p.Val600Asp, Heterozygous |
|---|
Manuseio
| Meio de cultura | EMEM (MEM Eagle), w: 2 mM L-Glutamine, w: 2.2 g/L NaHCO3, w: EBSS (Cytion article number 820100a) |
|---|---|
| Suplementos | Supplement the medium with 10% heat-inactivated FBS and 1% NEAA |
| Reagente de dissociação | Accutase |
| Densidade de semeadura | 1 to 3 x 104 cells/cm2 |
| Meio de congelamento | As a cryopreservation medium, we use complete growth medium + 10% DMSO for adequate post-thaw viability. |
| Descongelamento e cultura de células |
|
| Atmosfera de incubação | 37°C, 5% CO2, humidified atmosphere. |
| Condições de envio | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Condições de armazenamento | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Controle de Qualidade e Análise Molecular
| Local da metástase: | Melanoma |
|---|
Certificado de Análise (CoA)
| Número do lote | Tipo de certificado | Data | Número de catálogo |
|---|---|---|---|
| 305457-030226 | Certificado de Análise | 05. Mar. 2026 | 305457 |